Fate Therapeutics Inc

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC FATE

Report date

3/31/2026

Quarter

2026 Q1

Filed

5/13/2026

Shares

815

Value ($000)

1

Weight

0.0%

2019 Q4 - 2026 Q1 (19 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2026 Q1	5/13/2026	1	0.0%	815	3/31/2026
2024 Q3	11/14/2024	497	0.0%	142,131	9/30/2024
2024 Q2	8/14/2024	618	0.0%	188,460	6/30/2024
2023 Q3	11/13/2023	75	0.0%	35,408	9/30/2023
2023 Q2	8/11/2023	202	0.0%	35,408	6/30/2023
2023 Q1	5/15/2023	202	0.0%	35,408	3/31/2023
2022 Q4	2/14/2023	789	0.0%	78,151	12/31/2022
2022 Q3	11/14/2022	9,208	0.0%	410,893	9/30/2022
2022 Q2	8/12/2022	12,739	0.0%	514,097	6/30/2022
2022 Q1	5/16/2022	17,216	0.0%	444,050	3/31/2022
2021 Q4	2/14/2022	25,004	0.0%	427,343	12/31/2021
2021 Q3	11/15/2021	21,302	0.0%	359,409	9/30/2021
2021 Q2	8/16/2021	29,818	0.0%	343,567	6/30/2021
2021 Q1	5/14/2021	24,701	0.0%	299,593	3/31/2021
2020 Q4	3/1/2021	37,320	0.0%	410,425	12/31/2020
2020 Q3	11/13/2020	22,684	0.0%	567,536	9/30/2020
2020 Q2	8/14/2020	19,113	0.0%	557,074	6/30/2020
2020 Q1	5/15/2020	8,141	0.0%	366,557	3/31/2020
2019 Q4	2/14/2020	10,793	0.0%	551,496	12/31/2019